AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30661037 — intervention group
Group type: COMPARATOR
Intervention: Low educational attainment (primary school or illiterate)
Number of subjects: 3369
Study 30661097 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib (CombiDT)
Number of subjects: 34
Study 30661177 — intervention group
Group type: EXPERIMENTAL
Intervention: Danvatirsen 3 mg/kg
Number of subjects: 126
Study 30661177 — intervention group
Group type: EXPERIMENTAL
Intervention: Danvatirsen 200 mg flat dosing
Number of subjects: 126
Study 30661177 — intervention group
Group type: COMPARATOR
Intervention: Flat dosing regimen
Number of subjects: 126
Study 30661197 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 106
Study 30661491 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative remodeling
Number of subjects: 30
Study 30661491 — intervention group
Group type: COMPARATOR
Intervention: Nonnegative remodeling
Number of subjects: 30
Study 30662504 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Oscillation (DO)
Number of subjects: 8
Study 30662504 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 8
Study 30662958 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual rewards
Number of subjects: 0
Study 30662958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed rewards
Number of subjects: 0
Study 30662958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rewards)
Number of subjects: 0
Study 30662958 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual rewards for diabetes management, details on dosage and duration not available.
Number of subjects: 0
Study 30662958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed rewards for diabetes management, details on dosage and duration not available.
Number of subjects: 0
Study 30662958 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details on intervention not available.
Number of subjects: 0
Study 30662958 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30663068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 0
Study 30663107 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg b.d.
Number of subjects: 150
Study 30663107 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.d.
Number of subjects: 150
Study 30663346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota of patients with acute appendicitis
Number of subjects: 99
Study 30663346 — intervention group
Group type: COMPARATOR
Intervention: Fecal microbiota of healthy controls
Number of subjects: 99
Study 30663346 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant analyses
Number of subjects: 99
Study 30663346 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendiceal microbiota analysis
Number of subjects: 99
Study 30663562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide
Number of subjects: 0
Study 30663898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary lifestyle
Number of subjects: 602
Study 30663902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunasin
Number of subjects: 0
Study 30663902 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30664011 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔPCO2 measured at 2 hours after ICU admission
Number of subjects: 308
Study 30664011 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lactate concentration measured at 2 hours after ICU admission
Number of subjects: 308
Study 30664011 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous oxygen saturation measured at 2 hours after ICU admission
Number of subjects: 308
Study 30664011 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔPCO2 to arteriovenous oxygen content difference ratio
Number of subjects: 308
Study 30664483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghya Bharari Ekatra intervention delivered in 6 weekly sessions by trained community educators; includes games, discussions, self-reflections, and skill-building exercises.
Number of subjects: 0
Study 30664496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with TheraSphere yttrium-90 (TARE)
Number of subjects: 420
Study 30664496 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 420
Study 30664496 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival, time to symptomatic progression, objective response rate, disease control rate, quality-of-life assessment, and adverse events
Number of subjects: 420
Study 30664526 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic critical illness (≥ 14 ICU days with persistent organ dysfunction)
Number of subjects: 173
Study 30664564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 1 g/kg/dose infused at 3-5, 30, and 60 days post-hepatoportoenterostomy (HPE)
Number of subjects: 29
Study 30664564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 29
Study 30664876 — intervention group
Group type: EXPERIMENTAL
Intervention: HDV-specific CD8 T cells
Number of subjects: 28
Study 30665258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus granules
Number of subjects: 0
Study 30665804 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-detected sleep-disordered breathing (SDB) events
Number of subjects: 600
Study 30665804 — intervention group
Group type: EXPERIMENTAL
Intervention: CIED-detected atrial high rate episodes (AHREs)
Number of subjects: 600
Study 30665804 — intervention group
Group type: EXPERIMENTAL
Intervention: CIED-detected or clinical ventricular arrhythmic events
Number of subjects: 600
Study 30666472 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG-RR (photoplethysmographic respiratory rate)
Number of subjects: 201
Study 30666472 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG-RR
Number of subjects: 201
Study 30667281 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based acute treatments for ACS (including early dual antiplatelet therapy, heparins during hospitalization, reperfusion therapy for ST-segment-elevation myocardial infarction)
Number of subjects: 82196
Study 30667281 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for secondary prevention (including dual antiplatelet therapy, ACE inhibitors/ARBs, statins at discharge, smoking cessation, cardiac rehabilitation counseling)
Number of subjects: 82196
Study 30667281 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality rate
Number of subjects: 82196
Study 30667281 — intervention group
Group type: COMPARATOR
Intervention: In-hospital mortality in ST-segment-elevation myocardial infarction
Number of subjects: 82196
Study 30667281 — intervention group
Group type: COMPARATOR
Intervention: In-hospital mortality in non-ST-segment elevation ACS
Number of subjects: 82196
Study 30667348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of anticoagulation therapy after endovascular thrombus removal and stent placement
Number of subjects: 0
Study 30668184 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea dressings
Number of subjects: 0
Study 30668217 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV vaccine
Number of subjects: 639
Study 30668695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus lamivudine
Number of subjects: 120
Study 30668843 — intervention group
Group type: EXPERIMENTAL
Intervention: Early therapy (ET) - HIV-1-infected children
Number of subjects: 46
Study 30668843 — intervention group
Group type: EXPERIMENTAL
Intervention: Late therapy (LT) - HIV-1-infected children
Number of subjects: 46
Study 30668843 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-response (NR) - HIV-1-infected children
Number of subjects: 46
Study 30668843 — intervention group
Group type: COMPARATOR
Intervention: HIV-1-uninfected children (SR) - control group
Number of subjects: 46
Study 30668843 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 Ab levels to p31 and p17
Number of subjects: 46
Study 30668843 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 Ab levels to gp160 and gp41
Number of subjects: 46
Study 30669161 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided radiofrequency ablation (RFA)
Number of subjects: 30
Study 30669936 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Functional Scale-ICU (PRFS-ICU) assessment
Number of subjects: 20
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (78.2%)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (72.3%)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents (72.3%)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (57.4%)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI (HR=0.49, 95% CI 0.30-0.81, p=0.005)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke (HR=7.37, 95% CI 2.35-23.1, p=0.001)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (HR=0.51, 95% CI 0.27-0.94, p=0.032)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at admission (HR=0.81, 95% CI 0.69-0.94, p=0.006)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery involvement (HR=0.49, 95% CI 0.25-0.96, p=0.037)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated C-reactive protein (HR=2.50, 95% CI 1.24-5.00, p=0.01)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI level (p=0.024)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery involvement (p=0.015)
Number of subjects: 101
Study 30670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (p=0.002)
Number of subjects: 101
Study 30670372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivot program (comprehensive digital smoking cessation program)
Number of subjects: 319
Study 30670498 — intervention group
Group type: EXPERIMENTAL
Intervention: YH25448
Number of subjects: 0
Study 30670498 — intervention group
Group type: COMPARATOR
Intervention: osimertinib
Number of subjects: 0
Study 30670667 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasound indices (diaphragmatic thickening fraction, diaphragmatic excursion)
Number of subjects: 30
Study 30670667 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first liberation attempt
Number of subjects: 30
Study 30671005 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychological treatment based on Unified Protocol (UP)
Number of subjects: 165
Study 30671005 — intervention group
Group type: COMPARATOR
Intervention: Conventional psychological treatment
Number of subjects: 165
Study 30671005 — intervention group
Group type: COMPARATOR
Intervention: Conventional psychological treatment plus pharmacological treatment
Number of subjects: 165
Study 30671005 — intervention group
Group type: COMPARATOR
Intervention: Minimum intervention based on basic psychoeducational information
Number of subjects: 165
Study 30671005 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment only
Number of subjects: 165
Study 30671262 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical split conjunctival autograft using fibrin glue
Number of subjects: 15
Study 30671283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness for Interdisciplinary HCPs (MIHP) - an 8-week, group-based course with weekly meditation training, gentle yoga, and discussions.
Number of subjects: 18
Study 30662958 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30662958 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual rewards for diabetes management, details on dosage and duration not available
Number of subjects: 0
Study 30662958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed rewards for diabetes management, details on dosage and duration not available
Number of subjects: 0
Study 30662958 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details on intervention not available
Number of subjects: 0
Study 30672136 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sirolimus
Number of subjects: 18
Study 30672141 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 0
Study 30672141 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI plus histamine-2 (H2) blocker
Number of subjects: 0
Study 30672141 — intervention group
Group type: COMPARATOR
Intervention: Control (H2 blocker alone)
Number of subjects: 0
Study 30672141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough
Number of subjects: 0
Study 30672141 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest X-ray (CXR)
Number of subjects: 0
Study 30672141 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for respiratory indications
Number of subjects: 0
Study 30672309 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn/PSA ratio
Number of subjects: 480
Study 30672309 — intervention group
Group type: COMPARATOR
Intervention: PSA
Number of subjects: 480
Study 30672309 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn/PSA
Number of subjects: 480
Study 30672741 — intervention group
Group type: EXPERIMENTAL
Intervention: SOVA websites and enhanced usual care
Number of subjects: 0
Study 30672741 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care alone
Number of subjects: 0
Study 30673992 — intervention group
Group type: EXPERIMENTAL
Intervention: Avaxim (Hepatitis A Virus Vaccine)
Number of subjects: 614
Study 30674285 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 0
Study 30674285 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative binomial and beta-binomial models
Number of subjects: 0
Study 30674442 — intervention group
Group type: EXPERIMENTAL
Intervention: System A (deep learning algorithm for visual features)
Number of subjects: 63
Study 30674442 — intervention group
Group type: EXPERIMENTAL
Intervention: System B (sonification-derived diagnostic layer)
Number of subjects: 63
Study 30674442 — intervention group
Group type: EXPERIMENTAL
Intervention: Heuristic analysis of Systems A and B
Number of subjects: 63
Study 30674442 — intervention group
Group type: EXPERIMENTAL
Intervention: OBS analysis of raw sound dermoscopies
Number of subjects: 63
Study 30674442 — intervention group
Group type: EXPERIMENTAL
Intervention: OBS image analysis of spectrograms
Number of subjects: 63
Study 30674451 — intervention group
Group type: EXPERIMENTAL
Intervention: Three week cast immobilisation (n=83)
Number of subjects: 247
Study 30674451 — intervention group
Group type: EXPERIMENTAL
Intervention: Three week orthosis (n=80)
Number of subjects: 247
Study 30674451 — intervention group
Group type: COMPARATOR
Intervention: Six week cast immobilisation (n=84)
Number of subjects: 247
Study 30674731 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/d oral nitisinone
Number of subjects: 5
Study 30674905 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS) with systemically administered chemotherapy (liposomal doxorubicin or temozolomide)
Number of subjects: 5
Study 30674905 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS)
Number of subjects: 5
Study 30674905 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS) with systemically administered chemotherapy
Number of subjects: 5
Study 30675234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg, q3w) with platinum-doublet chemotherapy for up to 6 cycles, followed by maintenance therapy for non-progressors
Number of subjects: 283
Study 30675234 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (7.5 mg/kg, q3w) with platinum-doublet chemotherapy for up to 6 cycles, without maintenance therapy
Number of subjects: 283
Study 30675234 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (all patients)
Number of subjects: 283
Study 30675375 — intervention group
Group type: EXPERIMENTAL
Intervention: Service user-held Physical health plan (PHP) used for 6 months in two community mental health teams.
Number of subjects: 0
Study 30675375 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups and interviews with service users and clinical staff.
Number of subjects: 0
Study 30675373 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based motivational interviewing
Number of subjects: 67
Study 30675373 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study 30675961 — intervention group
Group type: EXPERIMENTAL
Intervention: EM-guided percutaneous lung biopsy
Number of subjects: 129
Study 30675961 — intervention group
Group type: EXPERIMENTAL
Intervention: EM-guided percutaneous lung biopsy with bronchoscopic sampling
Number of subjects: 129
Study 30676359 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults living with HIV
Number of subjects: 51
Study 30676359 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans with HIV
Number of subjects: 51
Study 30677263 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month responders (≥ 3% BMI reduction)
Number of subjects: 687
Study 30677263 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders (< 3% BMI reduction)
Number of subjects: 687
Study 30677460 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation (OLT)
Number of subjects: 80
Study 30678470 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin balanced infusion system (IBIS)
Number of subjects: 15
Study 30678703 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing digital ulcer (DU) classification
Number of subjects: 148
Study 30678703 — intervention group
Group type: EXPERIMENTAL
Intervention: New categorisation of DU (episodic, recurrent, chronic)
Number of subjects: 148
Study 30678703 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential items for DU evaluation
Number of subjects: 148
Study 30678713 — intervention group
Group type: EXPERIMENTAL
Intervention: SERI osteotomy
Number of subjects: 29
Study 30678753 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-molecule counting high-sensitivity troponin I (hsTnI) with normal range <6 ng/l
Number of subjects: 4021
Study 30679026 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-based regimens (folinic acid, fluorouracil, and oxaliplatin)
Number of subjects: 3223
Study 30679147 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 32
Study 30679151 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to Resources in the Community (ARC) navigation model
Number of subjects: 82
Study 30679151 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation services
Number of subjects: 82
Study 30679214 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive, multidose use of iodinated contrast during CTA and DSA
Number of subjects: 0
Study 30679214 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30679333 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified adductor canal (SAC) block
Number of subjects: 40
Study 30679333 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 40
Study 30679333 — intervention group
Group type: EXPERIMENTAL
Intervention: SAC block
Number of subjects: 40
Study 30679332 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexmedetomidine (1 mL dexmedetomidine 100 µg/mL + 4 mL ropivacaine 5 mg/mL)
Number of subjects: 22
Study 30679332 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic dexmedetomidine (1 mL saline + 4 mL ropivacaine 5 mg/mL)
Number of subjects: 22
Study 30679332 — intervention group
Group type: COMPARATOR
Intervention: Control (NoDex: 1 mL saline + 4 mL ropivacaine 7.5 mg/mL)
Number of subjects: 22
Study 30679337 — intervention group
Group type: EXPERIMENTAL
Intervention: Obturator Nerve Block (ONB)
Number of subjects: 60
Study 30679337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 60
Study 30679389 — intervention group
Group type: EXPERIMENTAL
Intervention: LB-100 (experimental cancer therapeutic)
Number of subjects: 0
Study 30680179 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain consumption
Number of subjects: 530176
Study 30680179 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined grain consumption
Number of subjects: 530176
Study 30680179 — intervention group
Group type: COMPARATOR
Intervention: Cereal exposure
Number of subjects: 530176
Study 30680225 — intervention group
Group type: EXPERIMENTAL
Intervention: DACC-coated dressing
Number of subjects: 0
Study 30680225 — intervention group
Group type: COMPARATOR
Intervention: Non-coated occlusive absorbent post-operative dressing
Number of subjects: 0
Study 30680237 — intervention group
Group type: EXPERIMENTAL
Intervention: Afalaza
Number of subjects: 49
Study 30680237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 30680407 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg and Grazoprevir 100 mg once daily for 10 days
Number of subjects: 24
Study 30680407 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir (EBR/GZR)
Number of subjects: 24
Study 30680449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing chemotherapy
Number of subjects: 2533
Study 30680449 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab-containing chemotherapy
Number of subjects: 2533
Study 30680449 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2533
Study 30680449 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ECOG score
Number of subjects: 2533
Study 30680449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 2533
Study 30680635 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised 5-repetition sit-to-stand test (5R-STS)
Number of subjects: 121
Study 30680635 — intervention group
Group type: EXPERIMENTAL
Intervention: Telesupervised 5-repetition sit-to-stand test (5R-STS)
Number of subjects: 121
Study 30680635 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised at-home assessment using the 5R-STS
Number of subjects: 121
Study 30680635 — intervention group
Group type: EXPERIMENTAL
Intervention: Telesupervised recording assessment
Number of subjects: 121